NCT05026710

Brief Summary

This multi-center trial is being completed to compare patient outcomes related to the Imajin silicone stent in comparison to non-silicone polyurethane stents after ureteroscopy. Eligible participants will be enrolled and randomly assigned to receive the Imajin silicone stent or a non-silicone stent. In addition, the participants will complete questionnaires and have follow-up information collected (approximately 60 days after surgery). The trial hypothesizes that a ureteral stent made of silicone, will have superior outcomes when compared to non-silicone stents.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
224

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Dec 2021

Typical duration for not_applicable

Geographic Reach
1 country

10 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 23, 2021

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 30, 2021

Completed
3 months until next milestone

Study Start

First participant enrolled

December 2, 2021

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 21, 2024

Completed
1.2 years until next milestone

Results Posted

Study results publicly available

October 28, 2025

Completed
Last Updated

October 28, 2025

Status Verified

October 1, 2025

Enrollment Period

2.6 years

First QC Date

August 23, 2021

Results QC Date

July 1, 2025

Last Update Submit

October 13, 2025

Conditions

Keywords

Ureteral stentUreteroscopyLithotripsy

Outcome Measures

Primary Outcomes (2)

  • Change in Patient-Reported Outcomes Measurement Information System (PROMIS®) Scores of Pain-intensity at 7 to 10 Days

    This is a 3-item survey which participants select a response for each item from 1=no pain to 5=very severe for intensity of their pain. The sum of responses is then converted into a T-score that ranges from 36.3 to 81.8, with higher scores indicating worse pain intensity. Change is defined as the difference in T-score from baseline to 7-10 days after surgery.

    Baseline, 7 to 10 days: Participants can fill out the survey at any time between 7 to 10 days after surgery.

  • Change in Patient-Reported Outcomes Measurement Information System (PROMIS®) Scores of Pain-interference at 7 to 10 Days

    This is a 6-item survey which participants select a response for each item from 1=not at all to 5=very much for how much pain interfered with their life. The sum of responses is then converted into a T-score that ranges from 41.0 to 78.3, with higher scores indicating worse pain interference. Change is defined as the difference in T-score from baseline to 7-10 days after surgery.

    Baseline, 7 to 10 days: Participants can fill out the survey at any time between 7 to 10 days after surgery.

Secondary Outcomes (7)

  • Change in Patient-Reported Outcomes Measurement Information System (PROMIS®) Scores of Pain-intensity at 4 to 6 Weeks

    Baseline, 4 to 6 weeks: Participants can fill out the survey at any time between 4 to 6 weeks after surgery.

  • Change in Patient-Reported Outcomes Measurement Information System (PROMIS®) Scores of Pain-interference at 4 to 6 Weeks

    Baseline, 4 to 6 weeks: Participants can fill out the survey at any time between 4 to 6 weeks after surgery.

  • Change in National Institutes of Health (NIH) Lower Urinary Tract Dysfunction Research Network (LURN) Symptoms Index (SI)-10 Scores at 7 to 10 Days

    Baseline, 7 to 10 days: Participants can fill out the survey at any time between 7 to 10 days after surgery.

  • Change in NIH LURN SI-10 Scores at 4 to 6 Weeks

    : Baseline, 4 to 6 weeks: Participants can fill out the survey at any time between 4 to 6 weeks after surgery. Baseline, 4 to 6 weeks: Participants can fill out the survey at any time between 4 to 6 weeks after surgery.

  • Composite Healthcare Utilization Metric Within 30 Days (WinRatio)

    up to 30 days

  • +2 more secondary outcomes

Study Arms (2)

Silicone (Coloplast Imajin Hydro) ureteral stent

EXPERIMENTAL
Device: Silicone (Coloplast Imajin Hydro) ureteral stent

Non-silicone (Polyurethane/Percuflex) ureteral stent (any manufacturer).

EXPERIMENTAL
Device: Non-silicone (Polyurethane/Percuflex) ureteral stent (any manufacturer)

Interventions

During the end of the standard of care ureteroscopy the silicone stent will be placed.

Silicone (Coloplast Imajin Hydro) ureteral stent

During the end of the standard of care ureteroscopy the Non-silicone (Polyurethane/Percuflex) stent will be placed.

Non-silicone (Polyurethane/Percuflex) ureteral stent (any manufacturer).

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Diagnosed with unilateral renal and/or ureteral stones with the largest less than or equal to (≤)2.0 cm in size measured on abdominal x-ray, Ultrasound or computerized tomography (CT) scan
  • Renal stone defined as only renal location of stone(s).
  • Ureteral stone defined as ureteral only or ureteral and renal stone(s).
  • Planned unilateral ureteroscopy with stent placement without stent string.
  • Ability to take oral medication.
  • Ability and willingness to complete and adhere to survey questions and responses throughout study duration.

You may not qualify if:

  • Known planned secondary or staged procedure
  • Presence of anatomical anomalies (for example (e.g.) solitary, horseshoe, fused crossed ectopia, pelvic kidney)
  • Presence of any prior urinary diversion (e.g. ileal conduit, orthotopic neobladder)
  • Presence of any indwelling ureteral stent prior to ureteroscopy
  • Presence of any indwelling nephrostomy tube prior to ureteroscopy
  • Ancillary ureteroscopy to treat residual fragments after percutaneous renal stone surgery
  • Renal stone located in calyceal diverticulum
  • No indication for stent placement (e.g. spontaneous passage)
  • Bladder stone location.
  • Pregnancy or lactation
  • Known allergic reactions to polyurethane or silicone

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (10)

Michigan Medicine

Ann Arbor, Michigan, 48109, United States

Location

Michigan Medicine

Brighton, Michigan, 48116, United States

Location

Chelsea Hospital (Saint Joseph Mercy)

Chelsea, Michigan, 48118, United States

Location

Henry Ford Macomb Hospital

Clinton Township, Michigan, 48038, United States

Location

Henry Ford Hospital

Detroit, Michigan, 48202, United States

Location

Ascension Hospital (Comprehensive Urology)

Novi, Michigan, 48374, United States

Location

William Beaumont Hospital (Michigan Institute of Urology)

Royal Oak, Michigan, 48073, United States

Location

William Beaumont Hospital (Michigan Institute of Urology)

Troy, Michigan, 48085, United States

Location

Henry Ford West Bloomfield Hospital

West Bloomfield, Michigan, 48322, United States

Location

Integrated Healthcare Association (IHA) (Saint Joseph Mercy Hospital)

Ypsilanti, Michigan, 48197, United States

Location

Related Publications (1)

  • Becker REN, DiBianco JM, Higgins AM, Konheim J, Kleer E, Leavitt D, King A, Kachroo N, Majdalany SE, Gandham D, Fernandez Moncaleano G, Conrado B, Shoemaker E, Daignault-Newton S, Dauw CA, Ghani KR. Daily Ecological Momentary Assessments of Pain and Ability to Work After Ureteroscopy and Stenting. J Endourol. 2024 Jun;38(6):545-551. doi: 10.1089/end.2023.0625.

MeSH Terms

Conditions

NephrolithiasisUreterolithiasis

Condition Hierarchy (Ancestors)

Kidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesUrolithiasisMale Urogenital DiseasesUreteral Diseases

Results Point of Contact

Title
Khurshid Ghani, MD
Organization
University of Michigan

Study Officials

  • Khurshid Ghani, MD, MS, FRCS

    University of Michigan

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Urology

Study Record Dates

First Submitted

August 23, 2021

First Posted

August 30, 2021

Study Start

December 2, 2021

Primary Completion

July 1, 2024

Study Completion

August 21, 2024

Last Updated

October 28, 2025

Results First Posted

October 28, 2025

Record last verified: 2025-10

Data Sharing

IPD Sharing
Will not share

Locations